Effects of angiotensin II AT1-receptor blockade on high fat diet-induced vascular oxidative stress and endothelial dysfunction in dahl salt-sensitive rats

Journal of Pharmacological Sciences

Volumn 121, Issue 2, 2013, Pages 95-102

  Kosaka, Shinji ^a,b   Pelisch, Nicolas ^a   Rahman, Matlubur ^a   Nakano, Daisuke ^a   Hitomi, Hirofumi ^a   Kobori, Hiroyuki ^a   Fukuoka, Noriyasu ^b   Kobara, Hideki ^a   Mori, Hirohito ^a   Masaki, Tsutomu ^a   Cervenka, Ludek ^c   Matsumura, Yasuo ^d   Houchi, Hitoshi ^b   Nishiyama, Akira ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b KAGAWA UNIVERSITY HOSPITAL   (Japan)

^c INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^d OSAKA MEDICAL COLLEGE   (Japan)

Author keywords

Angiotensin II (AngII); Dahl salt sensitive (DSS) rat; Endothelial dysfunction; High fat (HF) diet; Oxidative stress

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 2 RECEPTOR; HYDRALAZINE; OLMESARTAN; PROTEIN P22; PROTEIN P22 PHOSPHATE OXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; SODIUM CHLORIDE; SUPEROXIDE; THIOBARBITURIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CONTROLLED STUDY; DAHL SALT SENSITIVE RAT; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HYPERTENSION; LIPID DIET; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; RECEPTOR BLOCKING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VASODILATATION;

EID: 84874126862     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.12169FP     Document Type: Article

References (38)

1. Dimsdale JE, Ziegler M, Mills P, Berry C. Prediction of salt s ensitivity. Am J Hypertens. 1990;3:429-435.
2. Rocchini AP, Key J, Bondie D, Chico R, Moorehead C, Katch V, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321: 580-585. (Pubitemid 19212870)
3. Morrison RG, Mills C, Moran AL, Walton CE, Sadek MH, Mangiarua EI, et al. A moderately high fat diet promotes salt-sensitive hypertension in obese zucker rats by impairing nitric oxide production. Clin Exp Hypertens. 2007;29:369-381. (Pubitemid 47345881)
4. Nagae A, Fujita M, Kawarazaki H, Matsui H, Ando K, Fujita T. Effect of high fat loading in Dahl salt-sensitive rats. Clin Exp Hypertens. 2009;31:451-461.
5. Zhang H Y, Reddy S, Kotchen TA. A high sucrose, high linoleic acid diet potentiates hypertension in the Dahl salt sensitive rat. Am J Hypertens. 1999;12:183-187. (Pubitemid 29130420)
6. Reil TD, Barnard RJ, Kashyap VS, Roberts CK, Gelabert HA. Diet-induced changes in endothelial-dependent relaxation of the rat aorta. J Surg Res. 1999;85:96-100. (Pubitemid 29389973)
7. Lockette W, Otsuka Y, Carretero O. The loss of endothelium-dependent vascular relaxation in hypertension. Hypertension. 1986;8:II61-II66. (Pubitemid 16035840)
8. Crespo MJ, Escobales N, Rodriguez-Sargent C. Endothelial dysfunction in the San Juan hypertensive rat: possible role of the nitric oxide synthase. J Cardiovasc Pharmacol. 1996;27:802-808. (Pubitemid 26170839)
9. Roberts CK, Vaziri ND, Sindhu RK, Barnard RJ. A high-fat, refined-carbohydrate diet affects renal NO synthase protein expression and salt sensitivity. J Appl Physiol. 2003;94:941-946. (Pubitemid 36232007)
10. Tsai WC, Li YH, Lin CC, Chao TH, Chen JH. Effects of oxida-tive stress on endothelial function after a high-fat meal. Clin Sci (Lond). 2004;106:315-319.
11. Doran DE, Weiss D, Zhang Y, Griendling KK, Taylor WR. Differential effects of AT1 receptor and Ca2+ channel blockade on atherosclerosis, inflammatory gene expression, and production of reactive oxygen species. Atherosclerosis. 2007;195:39-47. (Pubitemid 47561942)
12. Shimada K, Murayama T, Yokode M, Kita T, Fujita M, Kishimoto C. Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production. Nutr Metab Cardiovasc Dis. 2011;21:672-678.
13. Nagai Y, Yao L, Kobori H, Miyata K, Ozawa Y, Miyatake A, et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol. 2005;16:703-711. (Pubitemid 41725107)
14. Koike H, Sada T, Mizuno M. In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist. J Hypertens Suppl. 2001;19:S3-S14. (Pubitemid 32587654)
15. Hitomi H, Kiyomoto H, Nishiyama A. Angiotensin II and oxida-tive stress. Curr Opin Cardiol. 2007;22:311-315.
16. Fardin NM, Oyama LM, Campos RR. Changes in baroreflex control of renal sympathetic nerve activity in high-fat-fed rats as a predictor of hypertension. Obesity (Silver Spring). 2012;20: 1591-1597.
17. Yan MX, Ren HB, Kou Y, Meng M, Li YQ. Involvement of nuclear factor kappa B in high-fat diet-related pancreatic fibrosis in rats. Gut Liver. 2012;6:381-387.
18. Nishiyama A, Kobori H, Fukui T, Zhang GX, Yao L, Rahman M, et al. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension. Hypertension. 2003;42: 754-760. (Pubitemid 37237321)
19. Nakano D, Kwak CJ, Fujii K, Ikemura K, Satake A, Ohkita M, et al. Sesamin metabolites induce an endothelial nitric oxide-dependent vasorelaxation through their antioxidative property-independent mechanisms: possible involvement of the metabolites in the antihypertensive effect of sesamin. J Pharmacol Exp Ther. 2006; 318:328-335.
20. Rahman M, Nishiyama A, Guo P, Nagai Y, Zhang GX, Fujisawa Y, et al. Effects of adrenomedullin on cardiac oxidative stress and collagen accumulation in aldosterone-dependent malignant hypertensive rats. J Pharmacol Exp Ther. 2006;318:1323-1329. (Pubitemid 44268342)
21. Nishiyama A, Fukui T, Fujisawa Y, Rahman M, Tian RX, Kimura S, et al. Systemic and regional hemodynamic responses to tempol in angiotensin II-infused hypertensive rats. Hypertension. 2001; 37:77-83. (Pubitemid 32064243)
22. Nishiyama A, Seth DM, Navar LG. Angiotensin II type 1 receptor-mediated augmentation of renal interstitial fluid angiotensin II in angiotensin II-induced hypertension. J Hypertens. 2003;21: 1897-1903. (Pubitemid 37290108)
23. Dobrian AD, Schriver SD, Lynch T, Prewitt RL. Effect of salt on hypertension and oxidative stress in a rat model of diet-induced obesity. Am J Physiol Renal Physiol. 2003;285:F619-F628. (Pubitemid 37140246)
24. Galili O, Versari D, Sattler KJ, Olson ML, Mannheim D, McConnell JP, et al. Early experimental obesity is associated with coronary endothelial dysfunction and oxidative stress. Am J Physiol Heart Circ Physiol. 2007;292:H904-H911.
25. Gaenzer H, Sturm W, Neumayr G, Kirchmair R, Ebenbichler C, Ritsch A, et al. Pronounced postprandial lipemia impairs endo-thelium-dependent dilation of the brachial artery in men. Cardio-vasc Res. 2001;52:509-516. (Pubitemid 33153114)
26. Vogel RA, Corretti MC, Plotnick GD. Effect of a single high-fat meal on endothelial function in healthy subjects. Am J Cardiol. 1997;79:350-354. (Pubitemid 27093313)
27. Marchesi S, Lupattelli G, Schillaci G, Pirro M, Siepi D, Roscini AR, et al. Impaired flow-mediated vasoactivity during postprandial phase in young healthy men. Atherosclerosis. 2000;153: 397-402. (Pubitemid 32120339)
28. Li R, Wang WQ, Zhang H, Yang X, Fan Q, Christopher TA, et al. Adiponectin improves endothelial function in hyperlipidemic rats by reducing oxidative/nitrative stress and differential regulation of eNOS/iNOS activity. Am J Physiol Endocrinol Metab. 2007;293:E1703-E1708. (Pubitemid 350255122)
29. De Luis DA, Conde R, Gonzalez Sagrado M, Aller R, Izaola O, Perez Castrillon JL, et al. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women. Eur Rev Med Pharmacol Sci. 2010;14:759-763.
30. Dohi T, Narui K, Kasai T, Takaya H, Inoshita A, Maeno K, et al. Effects of olmesartan on blood pressure and insulin resistance in hypertensive patients with sleep-disordered breathing. Heart Vessels. 2011;26:603-608.
31. Mizukawa M, Ohmori K, Obayashi A, Ishihara Y, Yoshida J, Noma T, et al. Effects of combined olmesartan and pravastatin on glucose intolerance and cardiovascular remodeling in a metabolic-syndrome model. Hypertens Res. 2009;32:617-624.
32. Rizzoni D, Pasini E, Flati V, Rodella LF, Paiardi S, Assanelli D, et al. Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. J Hypertens. 2008;26:1595-1601.
33. Dikalov S. Cross talk between mitochondria and NADPH oxidases. Free Radic Biol Med. 2011;51:1289-1301.
34. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, et al. Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation. 2012;125:1402-1413.
35. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59: 251-287. (Pubitemid 47481436)
36. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, et al. Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005;16:3631-3641. (Pubitemid 46211284)
37. Miura S, Fujino M, Hanzawa H, Kiya Y, Imaizumi S, Matsuo Y, et al. Molecular mechanism underlying inverse agonist of angio-tensin II type 1 receptor. J Biol Chem. 2006;281:19288-19295. (Pubitemid 44035433)
38. Viswanad B, Srinivasan K, Kaul CL, Ramarao P. Effect of tempol on altered angiotensin II and acetylcholine-mediated vascular responses in thoracic aorta isolated from rats with insulin resistance. Pharmacol Res. 2006;53:209-215. (Pubitemid 43247533)